L3Harris Technologies, Inc.
—- Market cap
- $45.86B
- Debt
- —
- Cash
- −$1.07B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $45.86B · View financials
Snapshot Sep 11, 2026, 10:57 AM ET
FY 2025 ·
Decision snapshot: LHX stock price near parity vs AMGN $246.29 current versus $227.82 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Implied fair value · at LHX's multiple
Snapshot Sep 11, 2026, 10:57 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 79% equity / 21% debt · EV / Revenue 6.83x · EV proxy / EBITDA proxy 17.61x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
L3HARRIS TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LOCKHEED MARTIN CORP
LHX vs LMT
NORTHROP GRUMMAN CORP /DE/
LHX vs NOC
BOEING CO
LHX vs BA
RTX Corp
LHX vs RTX
GENERAL DYNAMICS CORP
LHX vs GD
HEICO CORP
LHX vs HEI
REGENERON PHARMACEUTICALS, INC.
LHX vs REGN
BIOGEN INC.
LHX vs BIIB
VERTEX PHARMACEUTICALS INC / MA
LHX vs VRTX
Gilead Sciences, Inc.
LHX vs GILD
Moderna, Inc.
LHX vs MRNA
Eli Lilly and Company
LHX vs LLY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LHX can sustain its 9.8% growth while improving margins and ROIC, then hold or selectively add because the current premium to the P/E-implied value could be justified by better execution; otherwise, trim exposure because the stock screens above both the P/E-based implied price and the DCF range.
At $277.06, LHX trades 16.7% above the P/E-based implied price of $230.88, suggesting the market is paying up versus AMGN comparison. The stock is also above the top of AMGN-implied range at $647.75?
Supporting Metrics